MIM
ACET icon

MetLife Investment Management’s Adicet Bio ACET Stock Holding History

MetLife Investment Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,000
Closed -$38.9K – 2889
2023
Q2 		$38.9K Hold
1,000
– – ﹤0.01% 2909
2023
Q1 		$92.1K Hold
1,000
– – ﹤0.01% 2585
2022
Q4 		$143K Buy
1,000
+205
+26% +$51.2K ﹤0.01% 2436
2022
Q3 		$181K Hold
795
– – ﹤0.01% 2362
2022
Q2 		$186K Hold
795
– – ﹤0.01% 2378
2022
Q1 		$254K Buy
795
+285
+56% +$65.6K ﹤0.01% 2207
2021
Q4 		$143K Buy
+510
New +$87.5K ﹤0.01% 2263

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MetLife Investment Management's ACET Position: Q3 2023 in Review

MetLife Investment Management sold out of Adicet Bio (ACET) in Q3 2023, closing a stake of 1,000 shares — an estimated $38.9K sold.

MetLife Investment Management first reported a position in ACET in Q4 2021 and held it in 7 quarters. The position peaked at $254K in Q1 2022. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

  • MetLife Investment Management reported no remaining Adicet Bio position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 1,000 Adicet Bio shares in Q3 2023, an estimated $38.9K.
  • MetLife Investment Management first reported a position in Adicet Bio in Q4 2021 and held it in 7 quarters.
  • MetLife Investment Management's Adicet Bio position peaked at $254K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.